Analyst Ratings For NASDAQ:CTMX – CytomX Therapeutics (NASDAQ:CTMX)
Today, SunTrust Banks initiated coverage on NASDAQ:CTMX – CytomX Therapeutics (NASDAQ:CTMX) with a Buy with a price target of $38.00.
Some recent analyst ratings include
- 6/1/2018-SunTrust Banks initiated coverage with a Buy rating.
- 5/10/2018-Cowen Reiterated Rating of Buy.
- 1/5/2018-Citigroup initiated coverage with a Buy ➝ Buy rating.
- 10/4/2017-Oppenheimer Reiterated Rating of Hold.
Recent Insider Trading Activity For NASDAQ:CTMX – CytomX Therapeutics (NASDAQ:CTMX)
NASDAQ:CTMX – CytomX Therapeutics (NASDAQ:CTMX) has insider ownership of 8.50% and institutional ownership of 75.97%.
- On 5/1/2018 Debanjan Ray, CFO, sold 3,000 with an average share price of $26.52 per share and the total transaction amounting to $79,560.00.
- On 5/1/2018 Sean A Mccarthy, CEO, sold 19,578 with an average share price of $26.55 per share and the total transaction amounting to $519,795.90.
- On 4/2/2018 Debanjan Ray, CFO, sold 3,000 with an average share price of $28.12 per share and the total transaction amounting to $84,360.00.
- On 3/26/2018 Frederick W Gluck, Director, sold 5,000 with an average share price of $31.93 per share and the total transaction amounting to $159,650.00.
- On 3/2/2018 Debanjan Ray, CFO, sold 33,000 with an average share price of $29.99 per share and the total transaction amounting to $989,670.00.
- On 3/2/2018 Frederick W Gluck, Director, sold 16,181 with an average share price of $30.00 per share and the total transaction amounting to $485,430.00.
- On 3/2/2018 Rachel Humphrey, Insider, sold 16,160 with an average share price of $30.00 per share and the total transaction amounting to $484,800.00.
Recent Trading Activity for NASDAQ:CTMX – CytomX Therapeutics (NASDAQ:CTMX)
Shares of NASDAQ:CTMX – CytomX Therapeutics closed the previous trading session at 25.66 -0.00 0.02% with shares trading hands.